PeproMene, Bio

PeproMene Bio, Inc. Announces Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia in the Phase 1 Clinical Trial of PMB-CT01 at City of Hope

07.08.2025 - 18:06:45

PeproMene Bio, Inc. California

@ prnewswire.co.uk